Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flu-Mel Conditioning for Allogeneic HCT in Hematologic Malignancies
NCT00772811Phase 2Completed
- Sponsor
- Japan Adult Leukemia Study Group
- Start
- Jul 2001
- Primary completion
- Sep 2010
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fludarabine and melphalan in chronic lymphocytic leukemia (CLL), lymphoma and multiple myeloma (MM), sponsored by Japan Adult Leukemia Study Group. Primary endpoints: Engraftment at 9 years, Chimerism at 9 years and 3 more. Started Jul 2001; status: completed.
02
Drugs
fludarabinemelphalan
03
Conditions
chronic lymphocytic leukemia (CLL)lymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT00772811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00772811.